alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 23.1

Consent of Independent Registered Public
Accounting Firm

The Board of
Directors
Rimage Corporation:

We consent to the incorporation by reference in the registration
statements (Nos. 333-161262, 333-147344, 333-34788, 333-53875, 333-69550, 333-106901
and 333-127244) on Form S-8 of Rimage Corporation and subsidiaries of our
report dated March 12, 2010, with respect to the consolidated balance sheets of
Rimage Corporation and subsidiaries as of December 31, 2009 and 2008, and the
related consolidated statements of income, stockholders equity and
comprehensive income, and cash flows for each of the years in the three-year
period ended December 31, 2009, and the related financial statement schedule,
and our report dated March 12, 2010 with respect to the effectiveness of
internal control over financial reporting as of December 31, 2009, which
reports appear in the December 31, 2009 annual report on Form 10-K of Rimage
Corporation.

KPMG LLP

Minneapolis,
Minnesota
March 12, 2010

---
Form of Subscription Letter



 Exhibit 4.5 
 SUBSCRIPTION LETTER 
 TO: The Directors of THINKPLUS INVESTMENTS LIMITED (the “Company”, an
international business company incorporated under the laws of the British Virgin Islands) 
 We request you to allot to me Schedule shares of a
par value of US$1.00 (the “Subscription Shares”) at a subscription price of the par value of the shares. 
 We agree to take the Subscription
Shares subject to the Memorandum of Association and the Articles of Association of the Company and I authorise you to enter the following name and address in the share register of the Company: 
  

					
	 Name:
	 	  
	 	
			
	 Address:
	 	  
	 	
			
	 Tel:
	 	  
	 	
			
	 Fax:
	 	  
	 	

  

					
	Name of Registered Shareholder (as above):	 	  
	 	

  

					
	Per:	 	     /s/
	 	

  

					
	Signature of Individual or Authorised Signatory

  

					
	Date:	 	  
	 	

 Schedule 
  

									
	No	  	 Name
	  	Share
Number	    	 Address
	  	 Date

	1	  	Button Software Limited	  	5,586	    		  	27/Feb/2005
	2	  	Team Dragon International Limited	  	2,964	    	 Room B, 38F, Building C
 Electronic Science &
Technology Building
 No. 2070 Shen Nan Road
 Shenzhen, China
518031
 Fax: +86-755-8327-3598
 Tel:
+86-755-8327-3499
	  	10/Mar/2005
	3.	  	Inno Global Technology Limited	  	2,850	    	 Office Tower, Xin Xing Square
 Di Wang Commercial
Centre
 5002 Shen Nan Dong Road
 Shenzhen, China
518008
 Fax: +86-755-2583-0029
 Tel:
+86-755-8263-8888
	  	10/Mar/2005
<PAGE>   1


                                   EXHIBIT 23



                               ARTHUR ANDERSEN LLP


                    CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS



      As independent public accountants, we hereby consent to the incorporation
of our report included in this Form 10-K into the Company's previously filed
Registration Statement File Nos. 33-66980, 33-86230, 333-01874, 333-03865,
333-22943, 333-28717, 333-45991, 333-53413, 333-60321, 333-73201, and 333-82879.


                                       /s/ Arthur Andersen LLP



Phoenix, Arizona
   December 22, 2000
II 

111TH CONGRESS 

1ST SESSION S. 2551 

To suspend temporarily the duty on Fluthiacet-methyl. 

IN THE SENATE OF THE UNITED STATES 

OCTOBER 30, 2009 

Mr. BURRIS introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To suspend temporarily the duty on Fluthiacet-methyl. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SUSPENSION OF DUTY ON FLUTHIACET-METH4 YL. 

5 (a) IN GENERAL.—Subchapter II of chapter 99 of 

6 the Harmonized Tariff Schedule of the United States is 

7 amended by inserting in numerical sequence the following 

8 new heading: 


smartinez on DSKB9S0YB1PROD with BILLS
2 

•S 2551 IS

‘‘ 9902.03.31 Methyl[[2-chloro-4-fluoro5[(tetrahydro-3-oxo-1H,3H- 

[1,3,4]thiadiazolo[3,4- 

a]pyridazin-1- 

ylidene)amino]phenyl]- 

thio]acetate (Fluthiacetmethyl) (CAS No. 117337– 

19–6) (provided for in subheading 2934.99.15) and any 

formulations containing such 

compound (provided for in 

subheading 3808.93.15). ....... Free No change No change On or before 

12/31/2011 ’’. 

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies to articles entered, or withdrawn 

3 from warehouse for consumption, on or after the 15th day 

4 after the date of the enactment of this Act. 

Æ 


smartinez on DSKB9S0YB1PROD with BILLS
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          MAR-31-1999
<PERIOD-START>                             APR-01-1998
<PERIOD-END>                               MAR-31-1999
<CASH>                                       6,558,000
<SECURITIES>                                         0
<RECEIVABLES>                                2,607,000
<ALLOWANCES>                                         0
<INVENTORY>                                 70,042,000
<CURRENT-ASSETS>                            79,207,000
<PP&E>                                       1,819,000
<DEPRECIATION>                                 878,000
<TOTAL-ASSETS>                              89,365,000
<CURRENT-LIABILITIES>                       31,036,000
<BONDS>                                     26,731,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       143,000
<OTHER-SE>                                  31,455,000
<TOTAL-LIABILITY-AND-EQUITY>                89,365,000
<SALES>                                    252,675,000
<TOTAL-REVENUES>                           252,675,000
<CGS>                                      215,074,000
<TOTAL-COSTS>                              215,074,000
<OTHER-EXPENSES>                            26,112,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           2,714,000
<INCOME-PRETAX>                              8,775,000
<INCOME-TAX>                                 3,598,000
<INCOME-CONTINUING>                          5,177,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 5,177,000
<EPS-BASIC>                                        .90
<EPS-DILUTED>                                      .90


</TABLE>
#### In the Matter of Maria-Lucia Anghel, Appellant, v Richard F. Daines, as Commissioner of Health, et al., Respondents.

Submitted November 15, 2010;

decided January 18, 2011

Motion for leave to appeal dismissed upon the ground that the order sought to be appealed from does not finally determine the proceeding within the meaning of the Constitution and is not an order of the type provided for in CPLR 5602 (a) (2).
IN THE SUPREME COURT OF PENNSYLVANIA MIDDLE DISTRICT COMMONWEALTH OF PENNSYLVANIA, Respondent

v. CARLOS CASTILLO, Petitioner : : : : : : : : : : : No. 50 MAL 2015 Petition for Allowance of Appeal from the Order of the Superior Court

ORDER PER CURIAM AND NOW , this 10th day of June, 2015, the Petition for Allowance of Appeal is DENIED
.
-  Home 
        -  Health Information 
        -  For Health Professionals 
        -  Diabetes Discoveries & Practice Blog 
        -  Archive Results 

Diabetes Discoveries & Practice Blog

## Archive Results

                Results 1 - 1 of 1 for:                     **December 2022**

## DDP Blog: Best of 2022

Dec. 14, 20220 Comments

            Join us as we recap the most popular posts of 2022, plus three posts you may have missed.             Read more

## Blog Tools

### Subscribe

Subscribe to get blog updates.

### Share this page

FacebookXEmailWhatsAppLinkedInRedditPinterest

### Search

### About

**Diabetes Discoveries and Practice Blog**

### Tags

Patient Communication64

Research Advancements45

Complications of Diabetes35

Medication and Monitoring29

Practice Transformation25

Diabetes Prevention24

Patient Self-Management22

Obesity and Weight Management20

Social Determinants of Health19

New Technologies17

Diabetic Kidney Disease15

Type 1 Diabetes15

Nutrition12

Shared Decision-Making12

Community Health8

### Archive

April 20241

March 20241

Feb. 20241

Jan. 20241

Dec. 20231

Nov. 20231

Oct. 20231

Aug. 20231

July 20231

June 20232

May 20231

April 20231

March 20231

Feb. 20231

Jan. 20232

Dec. 20221

Nov. 20222

Oct. 20222

Sept. 20222

Aug. 20223

July 20222

June 20222

May 20222

April 20222

March 20222

Feb. 20222

Jan. 20222

Dec. 20212

Nov. 20211

Oct. 20212

Sept. 20212

Aug. 20212

July 20212

June 20213

May 20212

April 20212

March 20212

Feb. 20212

Jan. 20211

Dec. 20202

Nov. 20202

Oct. 20204

Sept. 20205

Aug. 20204

July 20203

June 20202

May 20202

April 20201

March 20202

Feb. 20203

Jan. 20202

Dec. 20193

Nov. 20192

Oct. 20192

Sept. 20193

Aug. 20193

July 20193

June 20192

May 20194

April 20192

March 20192

Feb. 20191

Jan. 20192

Dec. 20182

Nov. 20184

Oct. 20184

Sept. 20182

Aug. 20185

July 20183

June 20184

May 20185

April 20184

March 20183

Feb. 20184

Jan. 20183

Dec. 20173

Nov. 20174

Oct. 20172

Sept. 20174

### Disclaimer

We welcome comments; all comments must follow our comment policy.

Blog posts written by individuals from outside the government may be owned by the writer and graphics may be owned by their creator. In such cases, it is necessary to contact the writer, artist, or publisher to obtain permission for reuse.
#### The People of the State of New York ex rel. Gilbert O. Cameron, Appellant, v Dora B. Schirro et al., Respondents.

Submitted December 20, 2010;

decided February 10, 2011

*755Motion for leave to appeal dismissed upon the ground that the order sought to be appealed from does not finally determine the proceeding within the meaning of the Constitution.
Amendment to the Letter Agreement


 Exhibit 10.1 
 GENAERA CORPORATION 
 5110 Campus Drive 
 Plymouth Meeting, PA 19462 
 November 29, 2007 
 John L. Armstrong, Jr. 
 8 Amberfield Lane 
 Hockessin Chase 
 Hockessin, DE 19707 
 Dear Jack: 
 For and in consideration of the mutual promises contained herein
and other good and valuable consideration and intending to be legally bound, we have agreed to amend in its entirety the second paragraph of your letter agreement dated October 21, 2003, as amended by letter agreement dated November 29,
2005 and by letter agreement dated July 6, 2006, between you and Genaera Corporation as follows: 
 If (i) your employment is
terminated without “Cause,” as defined in Section 2.4 of the Genaera Corporation 2004 Stock Based Incentive Compensation Plan, except that clause (iv) of such Section shall not apply to the definition of “Cause” as used
in this letter agreement, or (ii) you terminate your employment at any time with Good Reason (as defined below), (a) you will receive your monthly base salary for twelve (12) months following the date of termination, (b) all of
your outstanding unvested options to purchase, or awards to acquire, securities of Genaera Corporation shall vest as of the date of termination and (c) all of your outstanding options to purchase, or awards to acquire, securities of Genaera
Corporation shall remain exercisable for the shorter of five (5) years following the date of termination or the original term of such option to purchase, or award to acquire, securities of Genaera Corporation. 
 All the terms and conditions of this letter agreement shall be binding upon and inure to the benefit and be enforceable by the respective heirs, representative heirs,
representative, successors (including any successor as a result of a merger or similar reorganization) and assigns of the parties hereto, except that your duties and responsibilities hereunder are of a personal nature and shall not be assignable in
whole or in part by you. All terms of the letter agreement dated October 21, 2003, as amended by letter agreement dated November 29, 2005 and by letter agreement dated July 6, 2006, between you and Genaera Corporation not amended by
this letter agreement shall remain in full force and effect. 






 Please indicate your agreement with the terms of this letter agreement by your signature below. 
 Sincerely, 
  

	
	 /s/ R. Frank Ecock

	R. Frank Ecock
	Chair, Compensation Committee
	
	Agreed to and Accepted:
	
	 /s/ John L. Armstrong, Jr.

	John L. Armstrong, Jr.
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

FOR THE NINTH CIRCUIT

KIMETRA BRICE; et al., 

Plaintiffs-Appellees, 

 v. 

SEQUOIA CAPITAL OPERATIONS, LLC; 

et al., 

Defendants, 

and 

7HBF NO. 2, LTD.; et al., 

Defendants-Appellants.

No. 19-17477 

D.C. No. 3:19-cv-01481-WHO 

MEMORANDUM∗

Appeal from the United States District Court

for the Northern District of California

William Horsley Orrick, District Judge, Presiding

Argued and Submitted September 16, 2020

San Francisco, California

Before: W. FLETCHER, FORREST**, and VANDYKE, Circuit Judges.

Dissent by Judge W. FLETCHER

∗

This disposition is not appropriate for publication and is not precedent 

except as provided by Ninth Circuit Rule 36-3. ** Formerly known as Danielle J. Hunsaker.

FILED

SEP 16 2021

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
2 

Defendants-appellants 7HBF NO. 2, LTD et al. appeal from the district 

court’s denial of their motion to compel arbitration.1 We have jurisdiction under 9 

U.S.C. § 16(a)(1)(A), (C), and we reverse and remand with instructions to stay the 

case and compel arbitration. We resolve this case for the reasons set forth in Brice 

v. Plain Green, No. 19-15707, __ F.3d __ (9th Cir. Sept. 16, 2021), a companion 

case involving different defendants but the same Borrowers, materially similar loan 

agreements, and the same underlying dispute over the enforceability of the 

arbitration agreements contained in Borrowers’ loan agreements. 

Here, as in Plain Green, we conclude that the parties agreed to arbitrate both 

their substantive disputes and any gateway questions regarding the arbitration 

agreement’s “validity, enforceability, or scope.” See __ F.3d at __; slip op. at 31; see

also Rent-A-Center, West, Inc. v. Jackson, 561 U.S. 63 (2010). The latter 

agreement—the delegation provision—does not prevent Borrowers from 

challenging enforceability based on prospective waiver or otherwise waive their 

rights to pursue federal statutory remedies. See Am. Express Co. v. Italian Colors 

Rest., 570 U.S. 228, 235 (2013). Therefore, we conclude that the delegation 

provision is not itself invalid as a prospective waiver and that it is for an arbitrator, 

1

This case was originally consolidated with another similar appeal, Brice v. 

Sequoia Capital Operations LLC, No. 19-17414, but the parties to that appeal 

settled after oral argument. The appeals were then severed, and No. 19-17414 was 

dismissed. 
3 

not the court, to decide whether the parties’ arbitration agreement is enforceable.

REVERSED and REMANDED with instructions to stay the case and 

compel arbitration. 
Brice v. 7HBF No.2, No. 19-17477

W. FLETCHER, Circuit Judge, dissenting:

For the reasons given in my dissent in Brice v. Plain Green, No. 19-15707,

___ F.3d ___ (9th Cir. 2021), I strongly but respectfully dissent. 

FILED

SEP 16 2021

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
#### The People of the State of New York, Respondent, v David Owens, Appellant.

[872 NYS2d 687]

Judgment, Supreme Court, New York County (Maxwell Wiley, J.), rendered on or about February 6, 2008, unanimously affirmed. No opinion. Order filed. Concur—Mazzarelli, J.P., Friedman, Buckley, Acosta and Freedman, JJ.
#### Simpson *v.*La Plata Mining & Smelting Co

*(Circuit Court, D. Colorado.*

July *2,*1883.

1. Negligence—Personal Injury to Mines.

A complaint in an action to recover damages for personal injuries caused by the negligence of an employer to ¡in employe, should clearly slate facts sufficient to make it appear to the court what the act of negligence that caused tlie injury was.

At Law.

*D. J. Haynes,*for plaintiff.

*Markham, Patterson & Thomas,*for defendant.

*126Hallett, J.,

*(orally.)*In the ease of William Simpson against the La Plata Mining & Smelting Company, an action to recover damages for injuries received while in the service of the company, the plaintiff-avers that the defendant, through its superintendent, brought into the smelting-house certain tanks or jackets, and stacked them up, or placed them on end, near where the plaintiff was required to pass,' in the performance of his usual duties, in wheeling out slag, and that while he was passing these tanks some one of them fell upon him and injured him. He has not described with particularity the position of the tanks, and what neglect there was in the superintendent in placing them where they were. He states briefly that the tanks were placed there, and that one of them fell upon him. I think that he should give in detail the position of the tanks, so that it may be seen what the act of negligence was on the part of the superintendent; how the tanks were placed, as evincing carelessness in the superintendent; and in what way they were left so as to be a source of danger to those who should pass by them. Certainly it is not enough to aver that the tanks were put there, and that one of them fell down. It may have been some extraordinary circumstance that caused the falling. If they were so placed that it might be reasonably expected they would topple over, he ought to state that fact—describe the position so clearly that we may see from the complaint that the superintendent was careless in leaving them in the way in which they were left.

Demurrer to complaint sustained, with leave to plaintiff to amend in 30 days.
**Exhibit 99.1**

 

**CERTIFICATION**

 

I, Howard W.Robin, Chief Executive Officer of Ribozyme Pharmaceuticals, Incorporated (the“Company”), pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dohereby certify as follows:

 

1.                                       Theannual report on Form 10-K of the Company for the period ended December 31,2002 fully complies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

 

2.                                       Theinformation contained in such Form 10-K fairly presents, in all materialrespects, the financial condition and results of operations of the Company.

 

IN WITNESS WHEREOF, I haveexecuted this Certification this 28th  day of March, 2003.

 

| /s/ Howard W. Robin                                     |
|---------------------------------------------------------|
| Howard W.  Robin  President and Chief Executive Officer |

 

 

I, MarvinTancer, Chief Financial Officer of Ribozyme Pharmaceuticals, Incorporated (the“Company”), pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dohereby certify as follows:

 

3.                                       Theannual report on Form 10-K of the Company for the period ended December 31,2002 fully complies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

 

4.                                       Theinformation contained in such Form 10-K fairly presents, in all materialrespects, the financial condition and results of operations of the Company.

 

IN WITNESS WHEREOF, I haveexecuted this Certification this 28th  day of March, 2003.

 

| /s/ Marvin Tancer                                                       |
|-------------------------------------------------------------------------|
| Marvin Tancer

Vice President of Operations and Chief Financial Officer |

 

 

----
<PAGE>   1
                                                                EXHIBIT 11.1



                       REDHOOK ALE BREWERY, INCORPORATED

                       COMPUTATION OF EARNINGS PER SHARE




<TABLE>
<CAPTION>

                                                                                                 YEAR ENDED DECEMBER 31,
                                                                                    ------------------------------------------------
                                                                                        1996               1995              1994
                                                                                    --------------    ---------------    -----------
<S>                                                                                  <C>                <C>                <C>
Primary and fully-diluted earnings per common share:
  Weighted average common shares outstanding ..............................          7,685,014          5,012,636          3,270,789

  Weighted average common stock equivalents outstanding:
    Series A convertible redeemable preferred stock .......................               --              796,791          1,242,857
    Series B convertible redeemable preferred stock .......................          1,289,872          1,289,872            163,006
    Stock options, net ....................................................            163,057            186,040            209,011

  Net effect of issuance of common stock and Series B preferred
    stock and the granting of stock options during the 12-month
    period prior to the offering at less than the offering price,
    calculated using the treasury stock method at the offering price,
    and treated as outstanding ............................................               --               13,273            394,089
                                                                                    ----------         ----------         ----------


Average number of common and equivalent shares outstanding ................          9,137,943          7,298,612          5,279,752
                                                                                    ==========         ==========         ==========

Net income ................................................................         $3,085,544         $3,182,453         $2,124,914
                                                                                    ==========         ==========         ==========

Earnings per share ........................................................         $     0.34         $     0.44         $     0.40
                                                                                    ==========         ==========         ==========
</TABLE>